Companion DTx: Clinical and economic evidence

Commercialization of DTx solutions as digital drug companions seems to be a valuable route to market for DTx companies and a good option for pharma companies, which are still wary of incorporating standalone DTx in their portfolios. However, there are still a lot of questions around the evidence generation for companion DTx. Join us in this informal conversation where we will talk about: